Roche $ROG (-0,68 %) has recently faced challenges in its pursuit of developing new obesity treatments, particularly with its GLP-1 drugs. Initial trial results had raised hopes for a potential blockbuster, showcasing significant weight loss among participants. However, recent disclosures about side effects, particularly high rates of vomiting, have led to a drop in Roche's stock prices, reflecting investor concerns.During recent trials, it was reported that about 75% of patients receiving the highest dose of Roche's CT-388 injection experienced vomiting. This revelation caused Roche's shares to decline by 4% on Monday and an additional 5% later in the week after similar findings were released for its oral weight-loss pill. Analysts noted that Roche's optimistic presentation of early trial data may have set unrealistic expectations, leading to a backlash when the side effects became apparent.The GLP-1 drug market is highly competitive, dominated by established players like Novo Nordisk and Eli Lilly. These companies have successfully launched treatments that not only aid in weight loss but also manage diabetes, with the market projected to grow significantly in the coming years. Analysts estimate that the GLP-1 market could reach $130 billion annually by 2030, driven by increasing demand for effective obesity and diabetes treatments.Despite the setbacks, Roche remains committed to its drug development, with company officials stating that the side effects observed are consistent with other GLP-1 treatments. They plan to adjust dosing strategies in future trials to improve tolerability. Other companies are also exploring new formulations and combinations of hormones to mitigate side effects and enhance efficacy, indicating that the race for effective obesity treatments is far from over.